Page last updated: 2024-12-07

ecteinascidin 743

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Ecteinascidin 743, also known as ET-743, is a potent anticancer drug isolated from the Caribbean tunicate Ecteinascidia turbinata. It exhibits a unique mechanism of action, inhibiting DNA replication and transcription by binding to the minor groove of DNA. ET-743 has shown promising activity against various cancers, including soft tissue sarcoma, breast cancer, and leukemia. Its complex structure presents a significant challenge for chemical synthesis, requiring multi-step procedures with low overall yields. The remarkable antitumor activity of ET-743 has led to extensive research efforts focused on its synthesis, structure-activity relationship studies, and development of analogs with improved pharmacological properties. ET-743 is currently undergoing clinical trials for various cancers, highlighting its potential as a valuable therapeutic agent.'
```

Cross-References

ID SourceID
PubMed CID108150
CHEMBL ID450449
CHEBI ID84050
SCHEMBL ID12119916
MeSH IDM0260321

Synonyms (66)

Synonym
et 743
ecteinascidine 743
trabectedin [inn]
nsc 648766
spiro(6,16-(epithiopropanoxymethano)-7,13-imino-12h-1,3-dioxolo(7,8)isoquino(3,2,-b)(3)benzazocine-20,1'(2'h)-isoquinolin)-19-one, 5-(acetyloxy)-3',4',6,6a,7,13,14,16-octahydro-6',8,14-trihydroxy-7',9-dimethoxy-4,10,23-trimethyl-, (1'r,6r,6ar,7r,13s,14s,1
spiro(6,16-(epithiopropanoxymethano)-7,13-imino-12h-1,3-dioxolo(7,8)isoquino(3,2,-b)(3)benzazocine-20,1'(2'h)-isoquinolin)-19-one, 3',4',6,6a,7,13,14,16-octahydro-5-(acetyloxy)-6',8,14-trihydroxy-7',9-dimethoxy-4,10,23-trimethyl-, (6r-(6-alpha,6a-beta,7-b
(1'r,6r,6ar,7r,13s,14s,16r)-6',8,14-trihydroxy-7',9-dimethoxy-4,10,23-trimethyl-19-oxo-3',4',6,7,12,13,14,16-octahydrospiro(6,16-(epithiopropanooxymethano)-7,13-imino-6ah-1,3-dioxolo(7,8)isoquino(3,2-b)(3)benzazocine-20,1'(2'h)-isoquinolin)-5-yl acetate
ect 743
gtpl2774
114899-77-3
nsc-684766
trabectedin ,
yondelis
et-743
NSC648766 ,
nsc-648766
NCGC00181159-01
nsc 684766
DB05109
NCGC00181159-02
unii-id0yzq2tcp
trabectedin [usan:inn:ban]
ccris 8133
ecteinascidin
id0yzq2tcp ,
ecteinascidins trabectedin
chebi:84050 ,
CHEMBL450449
tox21_113236
dtxsid2046880 ,
tox21_112762
cas-114899-77-3
dtxcid0026880
et743
ecteinascidins trabectedin [mi]
trabectedin [jan]
trabectedin [ema epar]
trabectedin [mart.]
trabectedin [usan]
trabectedin [who-dd]
trabectedin [orange book]
HY-50936
CS-1608
(6r,6ar,7r,13s,14s,16r,20r)-6',8,14-trihydroxy-7',9-dimethoxy-4,10,23-trimethyl-19-oxo-3',4',6,7,12,13,14,16-octahydro-2'h,6ah-spiro[7,13-epimino-6,16-(epithiopropanooxymethano)[1,3]dioxolo[7,8]isoquinolino[3,2-b][3]benzazocine-20,1'-isoquinolin]-5-yl ace
SCHEMBL12119916
AC-27767
ecteinascidin-743
AKOS025401985
(1r,2r,3r,11s,12s,14r,26r)-5,6',12-trihydroxy-6,7'-dimethoxy-7,21,30-trimethyl-27-oxo-3',4'-dihydro-2'h-17,19,28-trioxa-24-thia-13,30-diazaspiro[heptacyclo[12.9.6.1^{3,11}.0^{2,13}.0^{4,9}.0^{15,23}.0^{16,20}]triacontane-26,1'-isoquinoline]-4(9),5,7,15(23
[(1r,2r,3r,11s,12s,14r,26r)-5,6',12-trihydroxy-6,7'-dimethoxy-7,21,30-trimethyl-27-oxospiro[17,19,28-trioxa-24-thia-13,30-diazaheptacyclo[12.9.6.13,11.02,13.04,9.015,23.016,20]triaconta-4(9),5,7,15,20,22-hexaene-26,1'-3,4-dihydro-2h-isoquinoline]-22-yl] a
PKVRCIRHQMSYJX-AIFWHQITSA-N
Q2637746
EX-A4317
F81329
MS-31361
nsc813783
nsc-813783
EN300-19768451
ecteinascidin 743;et-743
trabectedinum
trabectedina
trabectedine
l01cx01
(1'r,6r,6ar,7r,13s,14s,16r)-6',8,14-trihydroxy-7',9-dimethoxy-4,10,23-trimethyl-19-oxo-3',4',6a,7,12,13,14,16-octahydro-2'h,6h-spiro(6,16-(epithiopropanooxymethano)-7,13-epiminobenzo(4,5)azocino(1,2-b)(1,3)dioxolo(4,5-h)isoquinolin-20,1'-isoquinolin)-5-yl
trabectedin (mart.)
(6r,6ar,7r,13s,14s,16r,20r)-6',8,14-trihydroxy-7',9-dimethoxy-4,10,23-trimethyl-19-oxo-3',4',6,7,12,13,14,16-octahydro-2'h,6ah-spiro(7,13-epimino-6,16-(epithiopropanooxymethano)(1,3)dioxolo(7,8)isoquinolino(3,2-b)(3)benzazocine-20,1'-isoquinolin)-5-yl ace

Research Excerpts

Overview

Ecteinascidin 743 (Et743) is a potent cytotoxic alkaloid of marine origin. It has shown promising evidence of antitumor activity during phase I clinical trials. The compound binds with sequence specificity to the minor groove of DNA and inhibits CBF-mediated transcriptional activation of numerous genes.

ExcerptReferenceRelevance
"Ecteinascidin 743 (Et743) is an interesting compound in phase II/III clinical trials. "( Ecteinascidin 743: a novel anticancer drug with a unique mechanism of action.
Aune, GJ; Furuta, T; Pommier, Y, 2002
)
3.2
"Ecteinascidin 743 (ET-743) is a potent cytotoxic alkaloid of marine origin that has shown promising evidence of antitumor activity during phase I clinical trials. "( Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity.
Butkiewicz, L; Demetri, GD; Garcia-Carbonero, R; Guzman, C; Harmon, D; Jimeno, J; Lopez-Lazaro, L; Maki, RG; Puchalski, TA; Ryan, DP; Seiden, MV; Supko, JG, 2002
)
2.08
"Ecteinascidin 743 (ET-743) is a potent antitumor agent from the Caribbean tunicate Ecteinascidia turbinata and is presently in clinical trials for human cancers. "( Sequence-dependent synergistic cytotoxicity of ecteinascidin-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo.
Banerjee, D; Bertino, JR; Brennan, MF; Chou, TC; Guan, Y; Li, W; Scotto, KW; Takahashi, N; Wada-Takahashi, Y, 2002
)
1.76
"Ecteinascidin 743 (Et-743) is a novel anticancer agent forming covalent guanine adducts at specific sites in the DNA minor groove. "( Overcoming multidrug drug resistance in P-glycoprotein/MDR1-overexpressing cell lines by ecteinascidin 743.
Akiyama, S; Kanzaki, A; Miyashita, H; Mori, S; Pommier, Y; Ren, XQ; Takebayashi, Y, 2002
)
1.98
"Ecteinascidin 743 (ET-743) is a chemotherapeutic agent that binds with sequence specificity to the minor groove of DNA and inhibits CBF-mediated transcriptional activation of numerous genes."( Transcriptional inhibition of type I collagen gene expression in scleroderma fibroblasts by the antineoplastic drug ecteinascidin 743.
Herrick, DJ; Jimenez, SA; Louneva, N; Saitta, B, 2003
)
1.25
"Ecteinascidin 743 (ET-743) is a new marine-derived agent with promising activity against a number of solid tumours. "( In vitro interaction between ecteinascidin 743 (ET-743) and radiation, in relation to its cell cycle effects.
De Pooter, CM; Faircloth, GT; Korst, AE; Lambrechts, HA; Lardon, F; Pattyn, GG; Simoens, C; Vermorken, JB, 2003
)
2.05
"Ecteinascidin 743 (Et743) is a highly cytotoxic anticancer agent isolated from the squirt Ecteinascidia turbinate, which alkylates DNA in the minor groove at GC-rich sequences resulting in an unusual bending toward the major groove. "( SV40 DNA replication inhibition by the monofunctional DNA alkylator Et743.
Beerman, TA; Dziegielewska, B; Kowalski, D, 2004
)
1.77
"Ecteinascidin 743 (ET-743) is a promising antitumoral drug for the treatment of soft tissues sarcomas, becoming a good candidate for clinical trials. "( Low cytotoxicity of ecteinascidin 743 in yeast lacking the major endonucleolytic enzymes of base and nucleotide excision repair pathways.
Bonatto, D; Henriques, JA; Poletto, NP; Salvador, M; Schwartsmann, G; Soares, DG, 2005
)
2.09
"Ecteinascidin 743 is a very potent anticancer compound and is administered in microgram m-2 dosages, which demands special requirements in terms of sensitivity for the analytical method supporting clinical pharmacokinetic studies."( Quantitative determination of Ecteinascidin 743 in human plasma by miniaturized high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
Beijnen, JH; Bult, A; Cvitkovic, E; Faircloth, G; Floriano, P; Gómez, A; Henrar, RE; Hillebrand, MJ; Jimeno, JM; Rosing, H; Vermorken, JB, 1998
)
1.31
"Ecteinascidin 743 (ET-743) is a cytotoxic tetrahydroisoquinoline alkaloid that covalently binds to DNA in the minor groove. "( Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies.
Clark, JW; Davis, J; Demetri, G; Eder, JP; Fischman, AJ; Jimeno, J; Lynch, TJ; Ryan, DP; Seiden, MV; Supko, JG, 2001
)
2.03
"Ecteinascidin 743 (ET-743) is a potent antitumor agent from the Caribbean tunicate Ecteinascidin turbinata and is presently in clinical trials for human cancers. "( Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells.
Banerjee, D; Bertino, JR; Li, WW; Scotto, KW; Takahashi, N, 2001
)
2
"Ecteinascidin 743 (ET-743) is a potent anti-tumoral agent of a marine origin. "( Search for metabolites of ecteinascidin 743, a novel, marine-derived, anti-cancer agent, in man.
Beijnen, JH; Cvitkovic, E; Hillebrand, MJ; Jimeno, JM; López-Lázaro, L; Manzanares, I; Rosing, H; Schellens, JH; Sparidans, RW; van Kesteren, C; van Oosterom, AT, 2001
)
2.05
"Ecteinascidin 743 (Et 743) is a potent antitumor marine alkaloid currently undergoing phase II clinical trials. "( Antitumor activity- and gene expression-based profiling of ecteinascidin Et 743 and phthalascidin Pt 650.
Corey, EJ; Martinez, EJ; Owa, T, 2001
)
1.75
"Ecteinascidin 743 (ET-743) is a novel, marine-derived anticancer agent currently under clinical development for the treatment of solid tumors. "( A comparison of limited sampling strategies for prediction of Ecteinascidin 743 clearance when administered as a 24-h infusion.
Beijnen, JH; Brain, E; Cvitkovic, E; Guzman, C; Hillebrand, MJ; Jimeno, JM; López-Lázaro, L; Mathĵt, RA; Misset, JL; Rosing, H; Schellens, JH; Taamma, A; van Kesteren, C, 2001
)
1.99
"Ecteinascidin 743 (ET-743) is an anticancer agent derived from the Caribbean tunicate Ecteinascidia turbinata. "( Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study.
Beijnen, JH; Bowman, A; Guzman, C; Hillebrand, MJ; Hoekman, K; Jimeno, J; López-Lázaro, L; Mathôt, RA; Rosing, H; Schellens, JH; Simpson, A; Smyth, J; Twelves, C; van Kesteren, C; Vermorken, JB, 2002
)
1.99

Toxicity

ExcerptReferenceRelevance
" As it was observed in different cancer cell lines, ET-743 was more toxic on an equimolar basis in human hematopoietic progenitors (inhibitory concentration reducing the viability to 50% after 24 h exposures; IC50(24h): 10-50 nM) compared with doxorubicin (IC50(24h) values: 280-460 nM), used as a control anticancer drug."( In vitro toxicity of ET-743 and aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors. comparison with the clinical results.
Albella, B; Bueren, JA; Faircloth, G; Guzmán, C; Jimeno, J; López-Lázaro, L, 2002
)
0.31
" Here the hypothesis was tested that dexamethasone can ameliorate manifestations of yondelis-induced hepatotoxicity in the female Wistar rat, which is the animal species with the highest sensitivity toward the adverse hepatic effect of yondelis."( Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat.
Colombo, T; D'Incalci, M; Donald, S; Frapolli, R; Gant, TW; Gescher, AJ; Greaves, P; Jimeno, J; Lopez-Lazaro, L; Meco, D; Riccardi, R; Verschoyle, RD; Zaffaroni, M; Zucchetti, M, 2003
)
0.32
"Long-term competitive repopulating assays were performed in mice to analyze toxic effects on the hematopoietic stem cells responsible for the multipotential long-term repopulation of hematopoiesis."( In vitro toxicity of three new antitumoral drugs (trabectedin, aplidin, and kahalalide F) on hematopoietic progenitors and stem cells.
Albella, B; Bueren, JA; Faircloth, GT; Gómez, SG; Jimeno, J, 2003
)
0.32
" Kahalalide F did not show any toxic effect in either short-term or long-term repopulating cells up to 10 microM."( In vitro toxicity of three new antitumoral drugs (trabectedin, aplidin, and kahalalide F) on hematopoietic progenitors and stem cells.
Albella, B; Bueren, JA; Faircloth, GT; Gómez, SG; Jimeno, J, 2003
)
0.32
" We tested the hypothesis that indole-3-carbinol (I3C), the hydrolysis product of glucosinolates occurring in cruciferous vegetables, may protect against ET-743-induced hepatotoxicity in the female Wistar rat, the animal species with the highest sensitivity toward the adverse hepatic effect of this drug."( Dietary agent indole-3-carbinol protects female rats against the hepatotoxicity of the antitumor drug ET-743 (trabectidin) without compromising efficacy in a rat mammary carcinoma.
Colombo, T; D'Incalci, M; Donald, S; Falcioni, C; Gescher, AJ; Greaves, P; Jimeno, J; Manson, MM; Steward, WP; Verschoyle, RD; Zaffaroni, M; Zucchetti, M, 2004
)
0.32
" Monitoring of plasma levels of liver enzymes ensures safe use of trabectedin in the clinic."( Hepatotoxicity and metabolism of trabectedin: a literature review.
Beijnen, JH; Beumer, JH; Schellens, JH, 2005
)
0.33
" CYP metabolites of ET-743 were less toxic compared with ET-743."( In-vitro cytotoxicity of ET-743 (Trabectedin, Yondelis), a marine anti-cancer drug, in the Hep G2 cell line: influence of cytochrome P450 and phase II inhibition, and cytochrome P450 induction.
Beijnen, JH; Brandon, EF; den Arend, D; Klijn, JS; Lázaro, LL; Meijerman, I; Schellens, JH; Sparidans, RW, 2005
)
0.33
" Drug-related grade 3 and 4 toxic effects were neutropenia (31%) and elevated transaminases (31%)."( A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies.
Bayever, E; Cardoso, TM; Cheng, JD; Cohen, RB; Renshaw, FG; Schilder, RJ; Temmer, E; von Mehren, M; Yuan, Z; Zannikos, P, 2008
)
0.35
"Drug-related cardiac adverse events (CAEs) were retrieved from phase I-III clinical trials, pharmacovigilance databases, and spontaneously reported cases."( Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis.
Alfaro, V; Gómez, J; Kahatt, C; Lardelli, P; Lebedinsky, C; Nieto, A; Parekh, T; Park, YC; Roy, E; Soto-Matos, A, 2011
)
0.37
" Nausea, fatigue and vomiting were the most common trabectedin-related adverse events, reported in ≥20% of patients."( A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials.
Blay, JY; Delaloge, S; Demetri, GD; Frontelo, P; Jiao, JJ; Le Cesne, A; Maki, RG; Misset, JL; Nieto, A; Yovine, A, 2012
)
0.38
" No unexpected toxicities were found, with neutropenia and transient increase in transaminases as the most common adverse events reported."( Safety profile of trabectedin in combination with liposomal pegylated doxorrubicin in relapsed ovarian carcinoma: considerations for optimal management.
González Martín, A, 2011
)
0.37
"This article extensively reviews the most common and specific adverse events associated with trabectedin."( Safety evaluation of trabectedin in treatment of soft-tissue sarcomas.
Judson, I; Martin-Liberal, J, 2013
)
0.39
" Specific adverse events such as liver toxicity and rhabdomyolysis do not usually have a significant clinical impact."( Safety evaluation of trabectedin in treatment of soft-tissue sarcomas.
Judson, I; Martin-Liberal, J, 2013
)
0.39
"4544GA), which has been suggested to play a role in excretion of toxic metabolites of trabectedin."( Irreversible hepatotoxicity after administration of trabectedin to a pleiomorphic sarcoma patient with a rare ABCC2 polymorphism: a case report.
Bétrian, S; Chatelut, E; Chevreau, C; Hennebelle, I; Laurenty, AP; Le Guellec, C; Le Guellec, S; Thomas, F, 2013
)
0.39
" The most common adverse drug reactions (ADRs) were myelosuppression and transient hepatic transaminase increases that were usually not clinically relevant."( A comprehensive safety evaluation of trabectedin and drug-drug interactions of trabectedin-based combinations.
De Sarro, G; Di Paola, ED; Gallelli, L; Leporini, C; Lucia, M; Patanè, M; Rende, P; Rossi, M; Russo, E; Saullo, F; Toscano, R, 2014
)
0.4
" The most common drug-related adverse events were nausea (65 %), fatigue (63 %), and neutropenia (53 %)."( Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies.
Bookman, M; Cohen, RB; Knoblauch, R; Li, J; Meropol, NJ; Parekh, T; Sherman, E; von Mehren, M; Weiner, LM, 2015
)
0.42
" Although this apparent favorable safety profile suggests a well-tolerated and manageable therapeutic option in the palliative care setting, trabectedin does have specific adverse side effects which can be hazardous for individual patients."( Trabectedin: Supportive care strategies and safety profile.
Jahn, F; Jordan, B; Jordan, K; Kegel, T; Müller-Tidow, C; Rüssel, J, 2015
)
0.42
" The safety profiles were consistent with the well-characterized toxicities of both agents, and the most common grade 3 to 4 adverse effects were myelosuppression and transient elevation of transaminases in the trabectedin arm."( Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.
Dean, A; Demetri, GD; Elias, A; Ganjoo, K; Hensley, ML; Jones, RL; Khokhar, NZ; Knoblauch, RE; Maki, RG; Milhem, M; Parekh, TV; Park, YC; Patel, SR; Schuetze, SM; Spira, A; Staddon, A; Tawbi, H; Van Tine, BA; von Mehren, M, 2016
)
0.43
" Protective strategies aiming at counteracting this important side effect have a crucial clinical impact."( Hepatoprotective effect of N-acetylcysteine in trabectedin-induced liver toxicity in patients with advanced soft tissue sarcoma.
Berruti, A; Bianchi, S; Consoli, F; Cosentini, D; Ferrari, VD; Grisanti, S; Lazzari, B; Roca, E; Tovazzi, V, 2018
)
0.48
"Grade 3 or higher adverse events occurred in 100 patients (71%) and included hepatotoxicity (37."( Efficacy and safety of trabectedin for patients with unresectable and relapsed soft-tissue sarcoma in Japan: A Japanese Musculoskeletal Oncology Group study.
Hayakawa, K; Iwata, S; Kobayashi, H; Oka, H; Tanaka, S; Ueda, T; Wakamatsu, T; Wasa, J; Yonemoto, T, 2020
)
0.56
"The dose-limiting toxic effects of trabectedin (phase 1) and the overall response rate (phase 2) with use of trabectedin plus irradiation in metastatic soft-tissue sarcomas."( Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas: A Nonrandomized Phase 1/2 Clinical Trial.
Alastuey, I; Alvarez, R; Alvarez-Gonzalez, A; Belinchon, B; Blay, JY; Coindre, JM; Cruz-Jurado, J; Dei Tos, AP; Dolado, MC; Gatti, M; Grignani, G; Gronchi, A; Gutierrez, A; Hindi, N; Isern-Verdum, J; Italiano, A; Lopez-Pousa, A; Luna, P; Martin-Broto, J; Martinez-Serra, J; Morosi, C; Moura, DS; Peinado-Serrano, J; Redondo, A; Rincon-Pérez, I; Romagosa, C; Romero, J; Sanchez-Bustos, P; Sargos, P; Sunyach, MP, 2020
)
0.56
" In phase 1, dose-limiting toxic effects included grade 4 neutropenia lasting more than 5 days in 1 patient at the starting dose level and a grade 4 alanine aminotransferase level increase in 1 of 6 patients at the +1 dose level."( Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas: A Nonrandomized Phase 1/2 Clinical Trial.
Alastuey, I; Alvarez, R; Alvarez-Gonzalez, A; Belinchon, B; Blay, JY; Coindre, JM; Cruz-Jurado, J; Dei Tos, AP; Dolado, MC; Gatti, M; Grignani, G; Gronchi, A; Gutierrez, A; Hindi, N; Isern-Verdum, J; Italiano, A; Lopez-Pousa, A; Luna, P; Martin-Broto, J; Martinez-Serra, J; Morosi, C; Moura, DS; Peinado-Serrano, J; Redondo, A; Rincon-Pérez, I; Romagosa, C; Romero, J; Sanchez-Bustos, P; Sargos, P; Sunyach, MP, 2020
)
0.56
"Patient data for multiple cardiac-related treatment-emergent adverse events (cTEAEs) were evaluated in pooled analyses of ten phase 2 trials, one phase 3 trial in STS (n = 982), and two phase 3 trials in ROC (n = 1231)."( Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer.
Coleman, RL; Demetri, GD; Herzog, TJ; Hu, P; Jones, RL; Knoblauch, R; McGowan, T; Monk, BJ; Patel, SR; Schuetze, SM; Shalaby, W; Triantos, S; Van Tine, BA; von Mehren, M, 2021
)
0.62
"6%) were the most common grade 3-5 adverse events related with trabectedin."( Efficacy and safety of trabectedin for the treatment of advanced uterine or ovarian carcinosarcoma: Results of a phase II multicenter clinical trial (MITO-26).
Bergamini, A; Bologna, A; Giolitto, S; Lorusso, D; Mangili, G; Mantero, M; Musacchio, L; Nicoloso, MS; Pignata, S; Pisano, C; Raspagliesi, F; Ronzulli, D; Salutari, V; Scambia, G; Tamberi, S, 2022
)
0.72
" Adverse events were manageable."( Real-World Experience of Efficacy and Safety of Trabectedin in Patients with Soft Tissue Sarcoma: A Bicentric Retrospective Analysis.
Aubry, S; Chaigneau, L; Charon Barra, C; Hervieu, A; Isambert, N; Jary, M; Kalbacher, E; Meynard, G; Nerich, V; Neumann, F, 2022
)
0.72

Pharmacokinetics

The study investigates the combined effects of gemcitabine and trabectedin (ecteinascidin 743) in two pancreatic cancer cell lines. It proposes a pharmacodynamic (PD) model to quantify their pharmacological interactions.

ExcerptReferenceRelevance
" Noncompartmental pharmacokinetic analysis was performed."( Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study.
Beijnen, JH; Brain, E; Cvitkovic, E; Guzman, C; Hillebrand, MJ; Jimeno, JM; López-Lázaro, L; Math t, RA; Misset, JL; Rosing, H; Schellens, JH; Taamma, A; van Kesteren, C, 2000
)
0.53
" Pharmacokinetic studies were performed on all patients for at least the first cycle, giving a linear pharmacokinetic profile; this showed a relationship between area under the curve (AUC) and transaminitis grade and a clear correlation between AUC and severe hematologic toxicity likelihood."( Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors.
Brain, E; Cvitkovic, E; Guzman, C; Jimeno, JM; Lopez Lazaro, L; Misset, JL; Riofrio, M; Rosing, H; Taamma, A, 2001
)
0.31
" The disposition of ET-743 was distinctly biexponential, and a departure from linear pharmacokinetic behavior was evident at the 1200-microg/m2 dose level."( Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies.
Clark, JW; Davis, J; Demetri, G; Eder, JP; Fischman, AJ; Jimeno, J; Lynch, TJ; Ryan, DP; Seiden, MV; Supko, JG, 2001
)
0.58
" For the Bayesian approach a three-compartment population pharmacokinetic model was developed; optimal time-points were selected using the D-optimality algorithm."( A comparison of limited sampling strategies for prediction of Ecteinascidin 743 clearance when administered as a 24-h infusion.
Beijnen, JH; Brain, E; Cvitkovic, E; Guzman, C; Hillebrand, MJ; Jimeno, JM; López-Lázaro, L; Mathĵt, RA; Misset, JL; Rosing, H; Schellens, JH; Taamma, A; van Kesteren, C, 2001
)
0.55
" Although the linear regression approach showed slightly better predictive performance, the Bayesian approach is preferred for the current phase II studies as it is more robust and flexible and allows the description of the full pharmacokinetic profile."( A comparison of limited sampling strategies for prediction of Ecteinascidin 743 clearance when administered as a 24-h infusion.
Beijnen, JH; Brain, E; Cvitkovic, E; Guzman, C; Hillebrand, MJ; Jimeno, JM; López-Lázaro, L; Mathĵt, RA; Misset, JL; Rosing, H; Schellens, JH; Taamma, A; van Kesteren, C, 2001
)
0.55
" infusion for 5 days every 3 weeks; (b) recommend a dose for Phase II studies; (c) characterize its pharmacokinetic behavior; and (d) seek preliminary evidence of anticancer activity."( A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies.
Beijnen, JH; Campbell, E; Eckhardt, SG; Guzman, C; Hidalgo, M; Jimeno, J; Kraynak, M; Lopez-Lazaro, L; Rosing, H; Rowinsky, EK; van Kesteren, C; Villalona-Calero, MA; Von Hoff, DD; Weiss, G, 2002
)
0.31
" Pharmacokinetic parameters were related to the principal toxicities."( A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies.
Beijnen, JH; Campbell, E; Eckhardt, SG; Guzman, C; Hidalgo, M; Jimeno, J; Kraynak, M; Lopez-Lazaro, L; Rosing, H; Rowinsky, EK; van Kesteren, C; Villalona-Calero, MA; Von Hoff, DD; Weiss, G, 2002
)
0.31
" Pharmacokinetic blood sampling was performed during the first cycle of therapy."( A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors.
Demetri, GD; Garcia-Carbonero, R; Harmon, D; Jimeno, J; Kuhlman, C; Maki, R; Manola, J; Merriam, P; Puchalski, T; Quigley, T; Ryan, DP; Supko, JG; Winkelman, J, 2002
)
0.58
" We conducted two sequential phase I dose escalation and pharmacokinetic studies of ET-743 given as a 1- or a 3-h intravenous (i."( Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours.
Anthoney, A; Beijnen, JH; Bowman, A; Gomez, J; Guzmán, C; Hanauske, A; Hoekman, K; Jimeno, J; Smyth, J; Twelves, C; Uiters, J; van Kesteren, C; Vermorken, JB; Wanders, J, 2003
)
0.32
"To assess the efficacy of the marine-derived alkaloid ecteinascidin 743 (ET-743) in patients with soft tissue sarcomas that progressed despite prior conventional chemotherapy and to characterize the pharmacokinetic profiles of ET-743 in this patient population."( Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.
Canniff, J; Demetri, GD; Garcia-Carbonero, R; Gomez, J; Goss, G; Guzman, C; Harmon, D; Jimeno, J; Lopez, T; Maki, RG; Manola, J; Matulonis, U; Merriam, P; Puchalski, TA; Quigley, MT; Ryan, DP; Sancho, MA; Seiden, MV; Supko, JG, 2004
)
0.84
" Pharmacokinetic studies were also performed."( Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.
Canniff, J; Demetri, GD; Garcia-Carbonero, R; Gomez, J; Goss, G; Guzman, C; Harmon, D; Jimeno, J; Lopez, T; Maki, RG; Manola, J; Matulonis, U; Merriam, P; Puchalski, TA; Quigley, MT; Ryan, DP; Sancho, MA; Seiden, MV; Supko, JG, 2004
)
0.59
" Pharmacokinetic sampling was done during the first treatment course."( A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children's Oncology Group study.
Baruchel, S; Bernstein, M; Blaney, S; Hershon, L; Jimeno, J; Krailo, M; Lau, L; Malkin, D; Qu, W; Seibel, N; Supko, JG, 2005
)
0.33
" The pharmacokinetics of ET-743 in 8 children was characterized by a terminal disposition phase with a mean half-life of 43."( A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children's Oncology Group study.
Baruchel, S; Bernstein, M; Blaney, S; Hershon, L; Jimeno, J; Krailo, M; Lau, L; Malkin, D; Qu, W; Seibel, N; Supko, JG, 2005
)
0.33
" Pharmacokinetic sampling was performed in 23 patients."( Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study.
Demetri, GD; Garcia-Carbonero, R; Goss, G; Guzman, C; Harmon, D; Jimeno, J; Lopez, T; Maki, RG; Manola, J; Puchalski, TA; Quigley, MT; Ryan, DP; Sancho, MA; Seiden, MV; Supko, JG; Waxman, A, 2005
)
0.33
" Severity of treatment-related toxicity was not correlated with pharmacokinetic variables."( Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study.
Demetri, GD; Garcia-Carbonero, R; Goss, G; Guzman, C; Harmon, D; Jimeno, J; Lopez, T; Maki, RG; Manola, J; Puchalski, TA; Quigley, MT; Ryan, DP; Sancho, MA; Seiden, MV; Supko, JG; Waxman, A, 2005
)
0.33
" An open four-compartment pharmacokinetic model with linear elimination, linear and nonlinear distribution to the deep and shallow peripheral compartments, respectively, and a catenary compartment off the shallow compartment was developed to best describe the index dataset using NONMEM V software."( Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patients.
Hirankarn, S; Lopez-Lazaro, L; Ludwig, EA; Owen, JS; Perez-Ruixo, JJ; Soto-Matos, A; Stuyckens, K; Zannikos, P, 2007
)
0.34
"The mean (SD) trabectedin elimination half-life was approximately 180 (61."( Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patients.
Hirankarn, S; Lopez-Lazaro, L; Ludwig, EA; Owen, JS; Perez-Ruixo, JJ; Soto-Matos, A; Stuyckens, K; Zannikos, P, 2007
)
0.34
" A semimechanistic pharmacokinetic and pharmacodynamic (PKPD) model was developed to evaluate the time course of alanine aminotransferase (ALT) elevation, tolerance development, and the hepatoprotective effect of dexamethasone on trabectedin-induced transient transaminitis following different dosing schedules in cancer patients."( Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment.
Fetterly, GJ; Izquierdo, MA; Owen, JS; Passarell, JA; Perez-Ruixo, JJ; Soto-Matos, A; Stuyckens, K; Zannikos, P, 2008
)
0.35
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
"To determine the maximum tolerated dose (MTD), safety, potential pharmacokinetic (PK) interactions, and effect on liver histology of trabectedin in combination with pegylated liposomal doxorubicin (PLD) for advanced malignancies."( A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies.
Bayever, E; Cardoso, TM; Cheng, JD; Cohen, RB; Renshaw, FG; Schilder, RJ; Temmer, E; von Mehren, M; Yuan, Z; Zannikos, P, 2008
)
0.35
" The pharmacokinetic profile of T and D at cycle 1 was analysed in 20 patients."( Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer.
Capri, G; Cresta, S; D'Incalci, M; De Braud, F; Feilchenfeldt, JW; Gallerani, E; Gianni, L; Ielmini, N; Jimeno, J; Locatelli, A; Noberasco, C; Perotti, A; Sessa, C; Viganò, L; Zucchetti, M, 2009
)
0.35
" The manageable toxicities at the MTDs, preliminary evidence of antitumor activity, pharmacokinetic profile, and the unique mechanistic aspects of trabectedin warrant further disease-directed evaluations on weekly schedules."( Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies.
Alfaro, V; Chu, Q; Forouzesh, B; Gómez, J; Hidalgo, M; Jimeno, J; Lebedinsky, C; Mita, A; Mita, M; Rowinsky, EK; Schwartz, G; Zintl, P, 2009
)
0.35
" No pharmacokinetic interaction was observed."( Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours.
Capri, G; Corradino, I; Cresta, S; D'Incalci, M; De Braud, F; Gallerani, E; Gianni, L; Locatelli, A; Marsoni, S; Minoia, C; Noberasco, C; Sessa, C; Zintl, P; Zucchetti, M, 2009
)
0.35
" Pharmacokinetic (PK) sampling was performed in the first 2 cycles."( Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors.
Barlow, C; Florez, A; Garcia, M; Judson, I; Kaye, SB; Lebedinsky, C; Magem, M; Montes, A; Pardo, B; Salazar, R; Vidal, L, 2012
)
0.38
" Plasma pharmacokinetic parameters were similar to historical data in adults."( A phase I trial and pharmacokinetic study of a 24-hour infusion of trabectedin (Yondelis®, ET-743) in children and adolescents with relapsed or refractory solid tumors.
Aikin, A; Balis, FM; Bayever, E; Chuk, MK; Fox, E; Whitcomb, T; Widemann, BC; Zannikos, P, 2012
)
0.38
" Comparison with population pharmacokinetic data suggests a PK interaction between trabectedin and cisplatin leading to increased plasma exposure of trabectedin in the first 48 h, lower platinum clearance and longer half-life."( Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors.
Alfaro, V; Christinat, A; Cresta, S; Del Conte, G; Fernández-Teruel, C; Gallerani, E; Gianni, L; Iglesias, JL; Kahatt, C; Lardelli, P; Perotti, A; Sessa, C, 2013
)
0.39
" Plasma samples were collected for pharmacokinetic analysis."( Phase I and pharmacokinetic study of trabectedin, a DNA minor groove binder, administered as a 24-h continuous infusion in Japanese patients with soft tissue sarcoma.
Ando, M; Kakunaga, S; Kawai, A; Sugiura, H; Ueda, T; Yamada, K; Yonemori, K, 2014
)
0.4
" Pharmacokinetic results for trabectedin plus docetaxel were similar to those previously reported for the single agents."( Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies.
Bookman, M; Cohen, RB; Knoblauch, R; Li, J; Meropol, NJ; Parekh, T; Sherman, E; von Mehren, M; Weiner, LM, 2015
)
0.42
"This study investigates the combined effects of gemcitabine and trabectedin (ecteinascidin 743) in two pancreatic cancer cell lines and proposes a pharmacodynamic (PD) model to quantify their pharmacological interactions."( Pharmacodynamic modeling of combined chemotherapeutic effects predicts synergistic activity of gemcitabine and trabectedin in pancreatic cancer cells.
Jusko, WJ; Koch, G; Miao, X; Straubinger, RM, 2016
)
0.66
"The adult population pharmacokinetic model adequately described the trabectedin plasma concentrations and its variability in the pediatric population of patients involved in this assessment that mostly comprised adolescents."( Population pharmacokinetics of trabectedin in adolescent patients with cancer.
Baruchel, S; Fox, E; Gonzalez, M; Hillewaert, V; Ouellet, D; Perez-Ruixo, JJ; Poggesi, I; Valenzuela, B, 2019
)
0.51

Compound-Compound Interactions

ExcerptReferenceRelevance
"To determine the maximum tolerated dose (MTD), safety, potential pharmacokinetic (PK) interactions, and effect on liver histology of trabectedin in combination with pegylated liposomal doxorubicin (PLD) for advanced malignancies."( A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies.
Bayever, E; Cardoso, TM; Cheng, JD; Cohen, RB; Renshaw, FG; Schilder, RJ; Temmer, E; von Mehren, M; Yuan, Z; Zannikos, P, 2008
)
0.35
"Trabectedin combined with PLD is generally well tolerated at therapeutic doses of both drugs in pretreated patients with diverse tumor types and appears to provide clinical benefit."( A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies.
Bayever, E; Cardoso, TM; Cheng, JD; Cohen, RB; Renshaw, FG; Schilder, RJ; Temmer, E; von Mehren, M; Yuan, Z; Zannikos, P, 2008
)
0.35
" Moreover, trabectedin combined with everolimus may be more efficacious for the management of CCC."( The activity of trabectedin as a single agent or in combination with everolimus for clear cell carcinoma of the ovary.
Hayashi, M; Hisamatsu, T; Kawase, C; Kimura, T; Kurachi, H; Mabuchi, S; Mimura, K; Sawada, K; Takahashi, K; Takahashi, T, 2011
)
0.37
" Thus our case underlines the importance of understanding rare treatment-related toxicities such as trabectedin-induced rhabdomyolysis and the possible role of the drug-drug interactions in the pathogenesis of this rare side effect."( Herbal-drug interaction induced rhabdomyolysis in a liposarcoma patient receiving trabectedin.
Albano, A; Guida, M; Lorusso, V; Strippoli, S, 2013
)
0.39
"Trabectedin (Yondelis(®)) is a potent marine-derived antineoplastic drug with high activity against various soft tissue sarcoma (STS) subtypes as monotherapy, and in combination with pegylated liposomal doxorubicin (PLD) for the treatment of patients with relapsed platinum-sensitive ovarian cancer."( A comprehensive safety evaluation of trabectedin and drug-drug interactions of trabectedin-based combinations.
De Sarro, G; Di Paola, ED; Gallelli, L; Leporini, C; Lucia, M; Patanè, M; Rende, P; Rossi, M; Russo, E; Saullo, F; Toscano, R, 2014
)
0.4
" Cardiac safety for trabectedin monotherapy (T) for STS or in combination with pegylated liposomal doxorubicin (T+PLD) for ROC was evaluated in this retrospective postmarketing regulatory commitment."( Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer.
Coleman, RL; Demetri, GD; Herzog, TJ; Hu, P; Jones, RL; Knoblauch, R; McGowan, T; Monk, BJ; Patel, SR; Schuetze, SM; Shalaby, W; Triantos, S; Van Tine, BA; von Mehren, M, 2021
)
0.62
"Trabectedin alone or in combination with cabozantinib inhibited tumor growth in PDX UM mouse models."( Preclinical Evaluation of Trabectedin in Combination With Targeted Inhibitors for Treatment of Metastatic Uveal Melanoma.
Alsafadi, S; Decaudin, D; Etienne, V; Gelmi, MC; Glinkina, K; Jager, MJ; Jochemsen, AG; Kuipers, MJ; Nemati, F; Teunisse, AFAS, 2022
)
0.72

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" In patients with advanced stage soft tissue sarcomas (ASTS), a dose-response relationship has been established for doxorubicin and ifosfamide."( [High-dose chemotherapy in soft tissue sarcomas of adults].
Biron, P; Blay, JY; Ray-Coquard, I, 2001
)
0.31
", and liver changes were assessed from 6 h up to 3 months after dosing by histopathology, immunohistochemistry, electron microscopy, hepatic and plasma biochemistry, and DNA microarray analysis."( Hepatobiliary damage and changes in hepatic gene expression caused by the antitumor drug ecteinascidin-743 (ET-743) in the female rat.
Davies, R; Dinsdale, D; Donald, S; Edwards, R; Gant, TW; Gescher, AJ; Greaves, P; Judah, DJ; Lopez Lazaro, L; Riley, J; Smith, AG; Verschoyle, RD, 2002
)
0.31
" Optimizing dosing strategies to further enhance the therapeutic index of ET-743 may depend upon obtaining a better understanding of the metabolic fate of the drug in humans."( Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity.
Butkiewicz, L; Demetri, GD; Garcia-Carbonero, R; Guzman, C; Harmon, D; Jimeno, J; Lopez-Lazaro, L; Maki, RG; Puchalski, TA; Ryan, DP; Seiden, MV; Supko, JG, 2002
)
0.64
" Additional studies to establish empirical dosing guidelines may be necessary to improve the safety of the drug in patients with varying degrees of hepatic dysfunction and definitively establish the role of ET-743 for patients with these malignancies."( Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study.
Demetri, GD; Garcia-Carbonero, R; Goss, G; Guzman, C; Harmon, D; Jimeno, J; Lopez, T; Maki, RG; Manola, J; Puchalski, TA; Quigley, MT; Ryan, DP; Sancho, MA; Seiden, MV; Supko, JG; Waxman, A, 2005
)
0.33
" The model evaluation procedure indicated accurate prediction of the observed incidence of neutropenia grades 3 and 4 across the dosing regimens evaluated."( Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia.
Hing, J; Lopez-Lazaro, L; Perez-Ruixo, JJ; Soto-Matos, A; Stuyckens, K; Zannikos, P, 2008
)
0.35
" A semimechanistic pharmacokinetic and pharmacodynamic (PKPD) model was developed to evaluate the time course of alanine aminotransferase (ALT) elevation, tolerance development, and the hepatoprotective effect of dexamethasone on trabectedin-induced transient transaminitis following different dosing schedules in cancer patients."( Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment.
Fetterly, GJ; Izquierdo, MA; Owen, JS; Passarell, JA; Perez-Ruixo, JJ; Soto-Matos, A; Stuyckens, K; Zannikos, P, 2008
)
0.35
" Simulations assessed the influence of dosing regimen and selected patient factors on the time course of ALT and the effectiveness of the dose reduction strategy."( Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment.
Fetterly, GJ; Izquierdo, MA; Owen, JS; Passarell, JA; Perez-Ruixo, JJ; Soto-Matos, A; Stuyckens, K; Zannikos, P, 2008
)
0.35
" While PM01183 and trabectedin appear functionally similar in cellular models, it is likely that the differences in pharmacokinetics may allow different dosing and scheduling of PM01183 in the clinic that could lead to novel and/or increased antitumor activity."( Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells.
Escargueil, AE; Galmarini, CM; Henriques, JA; Larsen, AK; Machado, MS; Ouaret, D; Poindessous, V; Rocca, CJ; Sarasin, A; Soares, DG, 2011
)
0.37
" For all patients enrolled in the trial, we evaluated the antiemetic regimen at the first cycle, acute and delayed CINV, any rescue therapy, any change in the prophylactic antiemetic regimen, and the potential relationship between dexamethasone dosage and incidence of CINV."( Emesis and nausea related to single agent trabectedin in ovarian cancer patients: a sub-study of the MITO15 project.
Arenare, L; Borgato, L; Cecere, SC; Della Pepa, C; Di Napoli, M; Ferrandina, G; Lepori, S; Lorusso, D; Mangili, G; Mosconi, AM; Pignata, S; Raspagliesi, F; Salutari, V; Salvino, A; Scambia, G; Sorio, R, 2017
)
0.46
" During the treatment period, the dosage and dose interval of trabectedin were optimized because of the appearance of grade 4 hematological and gastrointestinal toxicity."( Stable disease in a patient with metastatic leiomyosarcoma treated with trabectedin.
Amunni, G; Lavacchi, D; Mazzei, T; Montelatici, S; Tavella, K; Vannini, L; Villanucci, A, 2017
)
0.46
" Reduction in methadone dosage and liver supporting therapy was effective in reducing the drowsiness."( [A Case of Methadone Induced Drowsiness Following Trabectedin Induced Liver Injury].
Higuchi, M; Ishiki, H; Kiuchi, D; Satomi, E; Shimizu, M, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
marine metaboliteAny metabolite produced during a metabolic reaction in marine macro- and microorganisms.
anti-inflammatory agentAny compound that has anti-inflammatory effects.
angiogenesis modulating agentAn agent that modulates the physiologic angiogenesis process. This is accomplished by endogenous angiogenic proteins and a variety of other chemicals and pharmaceutical agents.
alkylating agentHighly reactive chemical that introduces alkyl radicals into biologically active molecules and thereby prevents their proper functioning. It could be used as an antineoplastic agent, but it might be very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. It could also be used as a component of poison gases.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (11)

ClassDescription
organic heteropolycyclic compound
azaspiro compoundAn azaspiro compound is a spiro compound in which at least one of the cyclic components is a nitrogen heterocyle.
oxaspiro compoundA spiro compound in which at least one of the cyclic components is an oxygen heterocyle.
bridged compoundA polycyclic compound in which two rings have two or more atoms in common.
lactoneAny cyclic carboxylic ester containing a 1-oxacycloalkan-2-one structure, or an analogue having unsaturation or heteroatoms replacing one or more carbon atoms of the ring.
polyphenolMembers of the class of phenols that contain 2 or more benzene rings each of which is substituted by at least one hydroxy group.
acetate esterAny carboxylic ester where the carboxylic acid component is acetic acid.
hemiaminalAny organic amino compound that has an amino group and a hydroxy group attached to the same carbon atom. Hemiaminals are intermediates in the formation of imines by addition of an amine to an aldehyde or ketone; those derived from primary amines are particularly unstable.
organic sulfideCompounds having the structure RSR (R =/= H). Such compounds were once called thioethers.
tertiary amino compoundA compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
isoquinoline alkaloidAny alkaloid that has a structure based on an isoquinoline nucleus. They are derived from the amino acids like tyrosine and phenylalanine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Drug induction of bile acid pathway025

Protein Targets (14)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
PPM1D proteinHomo sapiens (human)Potency0.08480.00529.466132.9993AID1347411
TDP1 proteinHomo sapiens (human)Potency0.00470.000811.382244.6684AID686978; AID686979
AR proteinHomo sapiens (human)Potency5.62940.000221.22318,912.5098AID743035; AID743036; AID743042; AID743053; AID743054; AID743063
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency20.76760.000214.376460.0339AID720691; AID720692
estrogen nuclear receptor alphaHomo sapiens (human)Potency0.47460.000229.305416,493.5996AID743069; AID743075; AID743078; AID743079; AID743080; AID743091
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency1.51050.001019.414170.9645AID743094; AID743140
aryl hydrocarbon receptorHomo sapiens (human)Potency0.22620.000723.06741,258.9301AID743085
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency0.03920.001723.839378.1014AID743083
nuclear receptor subfamily 1, group I, member 2Rattus norvegicus (Norway rat)Potency0.63100.10009.191631.6228AID1346983
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency0.00260.000323.4451159.6830AID743065; AID743066; AID743067
Interferon betaHomo sapiens (human)Potency0.08480.00339.158239.8107AID1347411
Cellular tumor antigen p53Homo sapiens (human)Potency0.01090.002319.595674.0614AID651631; AID720552
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency0.24340.011917.942071.5630AID651632
Ataxin-2Homo sapiens (human)Potency0.24340.011912.222168.7989AID651632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (170)

Processvia Protein(s)Taxonomy
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (44)

Processvia Protein(s)Taxonomy
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (28)

Processvia Protein(s)Taxonomy
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (68)

Assay IDTitleYearJournalArticle
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID403726Cytotoxicity against human A549 cells by sulforhodamine B assay2005Journal of natural products, Oct, Volume: 68, Issue:10
Halogenated helianane derivatives from the sponge Spirastrella hartmani.
AID502874Cytotoxicity against human A549 cells after 48 hrs by SRB assay2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Cytotoxicity of new pyrazino[1,2-b]isoquinoline and 6,15-iminoisoquino[3,2-b]3-benzazocine compounds.
AID348459Growth inhibition of human HT-29 cells after 48 hrs by MTT assay2008Bioorganic & medicinal chemistry, Oct-01, Volume: 16, Issue:19
Pyrazino[1,2-b]isoquinolines: synthesis and study of their cytostatic and cytotoxic properties.
AID329157Effect on cell cycle progression in Chinese hamster homologous recombination repair XRCC3 gene deficient irs1SF cells assessed as increase in accumulation at S phase at 6 nM for 1 hr followed by post incubation in drug-free media for 6 hrs relative to con2007Proceedings of the National Academy of Sciences of the United States of America, Aug-07, Volume: 104, Issue:32
Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.
AID502873Cytotoxicity against human MDA-MB-231 cells after 48 hrs by SRB assay2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Cytotoxicity of new pyrazino[1,2-b]isoquinoline and 6,15-iminoisoquino[3,2-b]3-benzazocine compounds.
AID329171Induction of chromosome damage in Chinese hamster V79 cells assessed as number of radials per 100 metaphases at 100 nM for 1 hr followed by post incubation in drug-free media for 24 hrs2007Proceedings of the National Academy of Sciences of the United States of America, Aug-07, Volume: 104, Issue:32
Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.
AID348456Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay2008Bioorganic & medicinal chemistry, Oct-01, Volume: 16, Issue:19
Pyrazino[1,2-b]isoquinolines: synthesis and study of their cytostatic and cytotoxic properties.
AID329162Effect on cell cycle distribution in Chinese hamster homologous recombination repair XRCC3 gene deficient irs1SF cells after 1 hr followed by post incubation in drug-free media2007Proceedings of the National Academy of Sciences of the United States of America, Aug-07, Volume: 104, Issue:32
Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.
AID329161Effect on cell cycle progression in Chinese hamster AA8 cells assessed as accumulation at S phase at 140 nM2007Proceedings of the National Academy of Sciences of the United States of America, Aug-07, Volume: 104, Issue:32
Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.
AID329166Induction of chromosome damage in Chinese hamster V79 cells assessed as number of damaged chromosomes per 100 metaphases at 10 nM for 1 hr followed by post incubation in drug-free media for 24 hrs2007Proceedings of the National Academy of Sciences of the United States of America, Aug-07, Volume: 104, Issue:32
Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID329158Effect on cell cycle progression in Chinese hamster homologous recombination repair XRCC3 gene deficient irs1SF cells assessed as increase in accumulation at G2/M phase at 6 nM for 1 hr followed by post incubation in drug-free media for 24 hrs relative to2007Proceedings of the National Academy of Sciences of the United States of America, Aug-07, Volume: 104, Issue:32
Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.
AID329153Cytotoxicity in homologous recombination repair XRCC3 gene deficient Chinese hamster irs1SF cells assessed as cell viability by MTT assay relative to wild type cells2007Proceedings of the National Academy of Sciences of the United States of America, Aug-07, Volume: 104, Issue:32
Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.
AID344982Growth inhibition of human MDA-MB-231 cells after 48 hrs by MTT assay2008Bioorganic & medicinal chemistry, Oct-01, Volume: 16, Issue:19
Pyrazino[1,2-b]isoquinolines: synthesis and study of their cytostatic and cytotoxic properties.
AID329175Induction of chromosome damage in BRCA2 deficient Chinese hamster V-C8 cells assessed as number of damaged chromosomes per 100 metaphases at 100 nM for 1 hr followed by post incubation in drug-free media for 24 hrs2007Proceedings of the National Academy of Sciences of the United States of America, Aug-07, Volume: 104, Issue:32
Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.
AID329151Induction of DNA double strand breaks in nonproliferating human lymphocytes at 100 nM by alkaline comet assay2007Proceedings of the National Academy of Sciences of the United States of America, Aug-07, Volume: 104, Issue:32
Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.
AID329144Reduction of DNA synthesis in human HeLa cells at 30 nM after 1 hrs by MTT assay2007Proceedings of the National Academy of Sciences of the United States of America, Aug-07, Volume: 104, Issue:32
Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.
AID329147Induction of DNA double strand breaks in Chinese hamster AA8 cells assessed as phosphorylated histone H2AX formation after 1 hr by immunostaining2007Proceedings of the National Academy of Sciences of the United States of America, Aug-07, Volume: 104, Issue:32
Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.
AID397095In vivo antitumor activity against mouse P388 cells at 15 ug/kg relative to control
AID329159Effect on cell cycle progression in Chinese hamster AA8 cells assessed as increase in accumulation at G2/M phase at 6 nM for 1 hr followed by post incubation in drug-free media for 6 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Aug-07, Volume: 104, Issue:32
Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.
AID329164Induction of DNA double strand breaks in Chinese hamster AA8 cells at 100 nM after 1 hr by comet assay2007Proceedings of the National Academy of Sciences of the United States of America, Aug-07, Volume: 104, Issue:32
Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.
AID329152Induction of DNA double strand breaks in human S-phase synchronized HeLa cells by alkaline comet assay2007Proceedings of the National Academy of Sciences of the United States of America, Aug-07, Volume: 104, Issue:32
Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.
AID329148Induction of DNA double strand breaks in human HeLa cells assessed as phosphorylated histone H2AX formation after 1 hr by immunostaining2007Proceedings of the National Academy of Sciences of the United States of America, Aug-07, Volume: 104, Issue:32
Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.
AID329145Reduction of cellular viability in human HeLa cells at 20 nM after 1 hr by MTT assay2007Proceedings of the National Academy of Sciences of the United States of America, Aug-07, Volume: 104, Issue:32
Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.
AID329154Cytotoxicity in homologous recombination repair BRCA2 gene deficient Chinese hamster V-C8 cells assessed as cell viability by MTT assay relative to wild type cells2007Proceedings of the National Academy of Sciences of the United States of America, Aug-07, Volume: 104, Issue:32
Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.
AID284235Cytotoxicity against human A459 cells after 48 hrs by MTT assay2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Synthesis and cytotoxic activity of pyrazino[1,2-b]-isoquinolines, 1-(3-isoquinolyl)isoquinolines, and 6,15-iminoisoquino[3,2-b]-3-benzazocines.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID329169Induction of chromosome damage in Chinese hamster V79 cells assessed as number of radials per 100 metaphases at 10 nM for 1 hr followed by post incubation in drug-free media for 24 hrs2007Proceedings of the National Academy of Sciences of the United States of America, Aug-07, Volume: 104, Issue:32
Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.
AID329174Induction of chromosome damage in BRCA2 deficient Chinese hamster V-C8 cells assessed as number of damaged chromosomes per 100 metaphases at 5 nM for 1 hr followed by post incubation in drug-free media for 24 hrs2007Proceedings of the National Academy of Sciences of the United States of America, Aug-07, Volume: 104, Issue:32
Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.
AID502875Cytotoxicity against human HT-29 cells after 48 hrs by SRB assay2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Cytotoxicity of new pyrazino[1,2-b]isoquinoline and 6,15-iminoisoquino[3,2-b]3-benzazocine compounds.
AID329146Induction of DNA double strand breaks in human HeLa cells after 1 hr by neutral comet assay2007Proceedings of the National Academy of Sciences of the United States of America, Aug-07, Volume: 104, Issue:32
Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.
AID329168Induction of chromosome damage in Chinese hamster V79 cells assessed as number of damaged chromosomes per 100 metaphases at 100 nM for 1 hr followed by post incubation in drug-free media for 24 hrs2007Proceedings of the National Academy of Sciences of the United States of America, Aug-07, Volume: 104, Issue:32
Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.
AID1377547Inhibition of MDR1 in human KB-C2 cells assessed as potentiation of vincristine-induced cytotoxicity by measuring fold reduction in vincristine IC502017European journal of medicinal chemistry, Sep-29, Volume: 138Natural alkaloids as P-gp inhibitors for multidrug resistance reversal in cancer.
AID348460Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay2008Bioorganic & medicinal chemistry, Oct-01, Volume: 16, Issue:19
Pyrazino[1,2-b]isoquinolines: synthesis and study of their cytostatic and cytotoxic properties.
AID329156Cytotoxicity in homologous recombination repair XRCC2 gene deficient Chinese hamster irs1 cells assessed as cell viability by MTT assay relative to wild type cells2007Proceedings of the National Academy of Sciences of the United States of America, Aug-07, Volume: 104, Issue:32
Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.
AID404018Cytotoxicity against human MDA-MB-231 cells by sulforhodamine B assay2005Journal of natural products, Oct, Volume: 68, Issue:10
Halogenated helianane derivatives from the sponge Spirastrella hartmani.
AID329170Induction of chromosome damage in Chinese hamster V79 cells assessed as number of radials per 100 metaphases at 50 nM for 1 hr followed by post incubation in drug-free media for 24 hrs2007Proceedings of the National Academy of Sciences of the United States of America, Aug-07, Volume: 104, Issue:32
Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.
AID329177Induction of chromosome damage in BRCA2 deficient Chinese hamster V-C8 cells assessed as number of radials per 100 metaphases at 2 nM for 1 hr followed by post incubation in drug-free media for 24 hrs2007Proceedings of the National Academy of Sciences of the United States of America, Aug-07, Volume: 104, Issue:32
Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID329180Induction of DNA double strand breaks in human CEM cells at 100 nM by alkaline comet assay2007Proceedings of the National Academy of Sciences of the United States of America, Aug-07, Volume: 104, Issue:32
Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.
AID284236Cytotoxicity against human HT29 cells after 48 hrs by MTT assay2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Synthesis and cytotoxic activity of pyrazino[1,2-b]-isoquinolines, 1-(3-isoquinolyl)isoquinolines, and 6,15-iminoisoquino[3,2-b]-3-benzazocines.
AID329155Cytotoxicity in homologous recombination repair RAD51C gene deficient Chinese hamster CL-V4B cells assessed as cell viability by MTT assay relative to wild type cells2007Proceedings of the National Academy of Sciences of the United States of America, Aug-07, Volume: 104, Issue:32
Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID329172Induction of chromosome damage in BRCA2 deficient Chinese hamster V-C8 cells assessed as number of damaged chromosomes per 100 metaphases at 1 nM for 1 hr followed by post incubation in drug-free media for 24 hrs2007Proceedings of the National Academy of Sciences of the United States of America, Aug-07, Volume: 104, Issue:32
Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.
AID329149Induction of DNA double strand breaks in human CEM cells assessed as phosphorylated histone H2AX formation after 1 hr by immunostaining2007Proceedings of the National Academy of Sciences of the United States of America, Aug-07, Volume: 104, Issue:32
Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.
AID329160Effect on cell cycle progression in Chinese hamster AA8 cells assessed as accumulation at G2 phase at 140 nM2007Proceedings of the National Academy of Sciences of the United States of America, Aug-07, Volume: 104, Issue:32
Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.
AID397093Cytotoxicity against mouse L1210 cells
AID329179Induction of chromosome damage in BRCA2 deficient Chinese hamster V-C8 cells assessed as number of radials per 100 metaphases at 10 nM for 1 hr followed by post incubation in drug-free media for 24 hrs2007Proceedings of the National Academy of Sciences of the United States of America, Aug-07, Volume: 104, Issue:32
Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.
AID329176Induction of chromosome damage in BRCA2 deficient Chinese hamster V-C8 cells assessed as number of radials per 100 metaphases at 1 nM for 1 hr followed by post incubation in drug-free media for 24 hrs2007Proceedings of the National Academy of Sciences of the United States of America, Aug-07, Volume: 104, Issue:32
Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.
AID404017Cytotoxicity against human HT-29 cells by sulforhodamine B assay2005Journal of natural products, Oct, Volume: 68, Issue:10
Halogenated helianane derivatives from the sponge Spirastrella hartmani.
AID329163Effect on cell cycle distribution in Chinese hamster AA8 cells assessed as isotoxic dose after 1 hr2007Proceedings of the National Academy of Sciences of the United States of America, Aug-07, Volume: 104, Issue:32
Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.
AID329165Induction of DNA double strand breaks in Chinese hamster homologous recombination repair XRCC3 gene deficient irs1SF cells at 100 nM after 1 hr by comet assay2007Proceedings of the National Academy of Sciences of the United States of America, Aug-07, Volume: 104, Issue:32
Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.
AID348457Growth inhibition of human A549 cells after 48 hrs by MTT assay2008Bioorganic & medicinal chemistry, Oct-01, Volume: 16, Issue:19
Pyrazino[1,2-b]isoquinolines: synthesis and study of their cytostatic and cytotoxic properties.
AID329167Induction of chromosome damage in Chinese hamster V79 cells assessed as number of damaged chromosomes per 100 metaphases at 50 nM for 1 hr followed by post incubation in drug-free media for 24 hrs2007Proceedings of the National Academy of Sciences of the United States of America, Aug-07, Volume: 104, Issue:32
Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.
AID329173Induction of chromosome damage in BRCA2 deficient Chinese hamster V-C8 cells assessed as number of damaged chromosomes per 100 metaphases at 2 nM for 1 hr followed by post incubation in drug-free media for 24 hrs2007Proceedings of the National Academy of Sciences of the United States of America, Aug-07, Volume: 104, Issue:32
Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.
AID348458Cytotoxicity against human A549 cells after 48 hrs by MTT assay2008Bioorganic & medicinal chemistry, Oct-01, Volume: 16, Issue:19
Pyrazino[1,2-b]isoquinolines: synthesis and study of their cytostatic and cytotoxic properties.
AID284234Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay2007Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
Synthesis and cytotoxic activity of pyrazino[1,2-b]-isoquinolines, 1-(3-isoquinolyl)isoquinolines, and 6,15-iminoisoquino[3,2-b]-3-benzazocines.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID329150Reversal of induction of DNA double strand breaks in human HeLa cells at >50 nM in presence of aphidicolin after 1 hr by neutral comet assay2007Proceedings of the National Academy of Sciences of the United States of America, Aug-07, Volume: 104, Issue:32
Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID329178Induction of chromosome damage in BRCA2 deficient Chinese hamster V-C8 cells assessed as number of radials per 100 metaphases at 5 nM for 1 hr followed by post incubation in drug-free media for 24 hrs2007Proceedings of the National Academy of Sciences of the United States of America, Aug-07, Volume: 104, Issue:32
Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1346802Mouse Pregnane X receptor (1I. Vitamin D receptor-like receptors)2001Nature medicine, May, Volume: 7, Issue:5
The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (643)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's15 (2.33)18.2507
2000's197 (30.64)29.6817
2010's342 (53.19)24.3611
2020's89 (13.84)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.60

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.60 (24.57)
Research Supply Index6.64 (2.92)
Research Growth Index5.45 (4.65)
Search Engine Demand Index31.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.60)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials102 (15.45%)5.53%
Reviews155 (23.48%)6.00%
Case Studies59 (8.94%)4.05%
Observational6 (0.91%)0.25%
Other338 (51.21%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]